Evidence map›Paper›PMID 33341119›Full record

ReviewJournal of biomedical science2020

Coronavirus vaccine development: from SARS and MERS to COVID-19.

Yen-Der Li, Wei-Yu Chi, Jun-Han Su, Louise Ferrall, Chien-Fu Hung, T-C Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of biomedical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Personalizing DNA Cancer Vaccines.Journal of personalized medicine · 2025
    Review
  19. Article
  20. Article

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yen-Der LiDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
Wei-Yu ChiDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Jun-Han SuDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
Louise FerrallDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Chien-Fu HungDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
T-C WuDepartment of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. wutc@jhmi.edu.ORCID http://orcid.org/0000-0003-1623-4584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. As a result, the academia, industry, and government sectors are working tightly together to develop and test a variety of vaccines at an unprecedented pace. In this review, we outline the essential coronavirus biological characteristics that are important for vaccine design. In addition, we summarize key takeaways from previous vaccination studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), highlighting the pros and cons of each immunization strategy. Finally, based on these prior vaccination experiences, we discuss recent progress and potential challenges of COVID-19 vaccine development.

Indexed as

COVID-19COVID-19 VaccinesVaccinationHumansMiddle East Respiratory Syndrome CoronavirusPandemicsSARS-CoV-2Severe acute respiratory syndrome-related coronavirusCOVID-19 VaccinesCoronavirusesSARS-CoV-2VaccineVaccine development

Identifiers

PMID33341119
PMCPMC7749790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.